Fulgent Genetics, Inc. (NASDAQ:FLGT) is reporting third quarter financial results on Monday 9th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, FLGT is expected to report 3Q20 income of $ 0.55 per share from revenue of $ 48.46 million.
For the full year, analysts anticipate top line of $ 131.99 million, while looking forward to income of $ 1.26 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 135.00 million ~ $ 135.00 million
Click Here For More Historical Outlooks Of Fulgent Genetics, Inc.
Previous Quarter Performance
Fulgent Genetics, Inc. announced income for the second quarter of $ 0.17 per share, from the revenue of $ 17.27 million. The quarterly earnings developed 183.33 percent while revenues escalated 169.00 percent compared with the same quarter last year. The top line results outshined analysts by $ 7.25 million or 72.36 percent.
Stock Performance
On Friday, shares of Fulgent Genetics, Inc. has traded high as $ 40.19 and has cracked $ 37.65 on the downward trend, reaching $ 40.02 with volume of 516.80 thousand shares.
According to the previous trading day, closing price of $ 40.02, representing a 477.91 % increase from the 52 week low of $ 6.70 and a 26.21 % decrease over the 52 week high of $ 52.47.
The company has a market capital of $ 896.62 million and is part of the Healthcare sector and Diagnostics & Research industry.
Recent Analyst recommendations
- On 25th September 2020, maintained by Credit Suisse Group at Neutral rating, with $ 42.00 target price.
Conference Call
Fulgent Genetics, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.fulgentgenetics.com
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions.
